423 related articles for article (PubMed ID: 22627678)
21. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
[TBL] [Abstract][Full Text] [Related]
22. Midostaurin approved for FLT3-mutated AML.
Levis M
Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
[TBL] [Abstract][Full Text] [Related]
23. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
24. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Voso MT; Larson RA; Jones D; Marcucci G; Prior T; Krauter J; Heuser M; Lavorgna S; Nomdedeu J; Geyer SM; Walker A; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte TM; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Amadori S; Cheng Y; Chen Y; Pallaud C; Du L; Piciocchi A; Ehninger G; Byrd J; Thiede C; Döhner K; Stone RM; Döhner H; Bloomfield CD; Lo-Coco F
Blood Adv; 2020 Oct; 4(19):4945-4954. PubMed ID: 33049054
[TBL] [Abstract][Full Text] [Related]
25. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
[TBL] [Abstract][Full Text] [Related]
26. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
27. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Tollkuci E
J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
[TBL] [Abstract][Full Text] [Related]
28. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
[TBL] [Abstract][Full Text] [Related]
29. Updated safety of midostaurin plus chemotherapy in newly diagnosed
Roboz GJ; Strickland SA; Litzow MR; Dalovisio A; Perl AE; Bonifacio G; Haines K; Barbera A; Purkayastha D; Sweet K
Leuk Lymphoma; 2020 Dec; 61(13):3146-3153. PubMed ID: 32812818
[TBL] [Abstract][Full Text] [Related]
30. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
31. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Wang ES
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France.
Tremblay G; Cariou C; Recher C; Dolph M; Brandt P; Blanc AS; Forsythe A
Eur J Health Econ; 2020 Jun; 21(4):543-555. PubMed ID: 31970530
[TBL] [Abstract][Full Text] [Related]
33. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Stone RM; DeAngelo DJ; Klimek V; Galinsky I; Estey E; Nimer SD; Grandin W; Lebwohl D; Wang Y; Cohen P; Fox EA; Neuberg D; Clark J; Gilliland DG; Griffin JD
Blood; 2005 Jan; 105(1):54-60. PubMed ID: 15345597
[TBL] [Abstract][Full Text] [Related]
34. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
[TBL] [Abstract][Full Text] [Related]
35. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
36. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
37. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
38. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H; Weber D; Krzykalla J; Fiedler W; Wulf G; Salih H; Lübbert M; Kühn MWM; Schroeder T; Salwender H; Götze K; Westermann J; Fransecky L; Mayer K; Hertenstein B; Ringhoffer M; Tischler HJ; Machherndl-Spandl S; Schrade A; Paschka P; Gaidzik VI; Theis F; Thol F; Heuser M; Schlenk RF; Bullinger L; Saadati M; Benner A; Larson R; Stone R; Döhner K; Ganser A
Blood Adv; 2022 Sep; 6(18):5345-5355. PubMed ID: 35486475
[TBL] [Abstract][Full Text] [Related]
39. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with
Schlenk RF; Weber D; Fiedler W; Salih HR; Wulf G; Salwender H; Schroeder T; Kindler T; Lübbert M; Wolf D; Westermann J; Kraemer D; Götze KS; Horst HA; Krauter J; Girschikofsky M; Ringhoffer M; Südhoff T; Held G; Derigs HG; Schroers R; Greil R; Grießhammer M; Lange E; Burchardt A; Martens U; Hertenstein B; Marretta L; Heuser M; Thol F; Gaidzik VI; Herr W; Krzykalla J; Benner A; Döhner K; Ganser A; Paschka P; Döhner H;
Blood; 2019 Feb; 133(8):840-851. PubMed ID: 30563875
[TBL] [Abstract][Full Text] [Related]
40. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M
Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
